This review provides a systematic strategy for optimizing monoclonal antibody manufacturing processes, offering direct guidance for biopharmaceutical development, particularly in reducing production costs and enhancing formulation stability.
Literature Overview
The article 'Advances in Downstream Processing of Monoclonal Antibodies,' published in the journal Antibodies, systematically examines key bottlenecks and emerging technologies in downstream processing (DSP) of monoclonal antibodies (mAbs). As mAbs grow increasingly important in therapeutics, their high production costs have become a major barrier to widespread use. Although upstream processing (USP) has significantly improved expression titers, downstream processing still accounts for up to 70% of total manufacturing costs, forming a critical bottleneck. The article comprehensively reviews existing platform technologies in the three core DSP steps—capture, polishing, and formulation—and focuses on the potential of non-chromatographic alternatives, particularly strategies such as precipitation, aqueous two-phase extraction, and crystallization. The authors also emphasize the critical role of continuous processing and novel material development in enhancing DSP efficiency.Background Knowledge
1. The key challenges addressed in this study regarding monoclonal antibodies are their high production costs and complex purification processes, especially the reliance on expensive Protein A resins and large volumes of buffers during capture and polishing steps, leading to poor process economics. Additionally, stability issues in final formulations limit long-term storage and ease of transportation.
2. Current research bottlenecks for Protein A focus on high ligand costs, poor alkali resistance, and ligand leaching, all of which limit resin lifespan. Meanwhile, traditional chromatography methods face declining dynamic binding capacity and non-specific adsorption when processing high-titer harvests, negatively impacting purity and yield.
3. The research切入点 lies in exploring 'anything but chromatography' strategies, introducing non-traditional methods such as precipitation, extraction, and crystallization to reduce dependence on Protein A and advance continuous, integrated DSP platforms. The article particularly highlights crystallization as a dual-function technology combining purification and formulation, offering a new pathway for future mAb product development.
Research Methods and Experiments
The authors employ a literature review and comparative technical analysis to systematically summarize recent advancements in mAb downstream processing. The study covers various experimental systems, including industrial-scale chromatography (e.g., Protein A, IEX, HIC), membrane adsorption, magnetic nanoparticles, and continuous multi-column chromatography (e.g., SMB, PCC). By comparing purity, yield, buffer consumption, and cost across different technologies, the authors assess their applicability in capture, polishing, and formulation steps. Notably, the article cites several case studies, such as PEG-assisted precipitation combined with solid-liquid extraction achieving 99% pure mAb recovery, and a continuous ATPS-HIC integrated platform reaching 99.6% purity, validating the feasibility of non-chromatographic methods.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a clear technological roadmap for industrial-scale mAb production. By advancing continuous, non-chromatographic, and integrated DSP strategies, it offers the potential to significantly reduce manufacturing costs and improve drug accessibility. Particularly, crystallization as a solid-formulation alternative to lyophilization could transform the current liquid-dominant mAb dosage landscape, enhancing drug stability and patient convenience.
From a research perspective, the review underscores the importance of multidisciplinary integration—combining chemical engineering, materials science, and biotechnology—to develop novel separation media and process control strategies. Future research should focus on standardizing platform non-chromatographic technologies and validating their robustness and scalability under GMP conditions.
Conclusion
The broad application of monoclonal antibody therapeutics is constrained by high production costs, with downstream processing being the key to cost control. This article systematically summarizes current technical bottlenecks and cutting-edge advances in DSP platforms, identifying a clear trend toward continuous, non-chromatographic, and crystallization-based processes. By adopting alternative methods such as precipitation, aqueous two-phase extraction, and crystallization, it is possible to significantly reduce buffer and resin consumption while improving product stability and process economics. Notably, crystallization, which combines purification and formulation functions, has the potential to become a core step in next-generation mAb manufacturing. These technological advances will accelerate the translation of mAb therapeutics from lab to clinic, enhance global access to biologics, and lay a more efficient and sustainable foundation for monoclonal antibody-based healthcare systems.
